(S)-1-(3,3-二甲基-2-氧戊烷酰基)哌啶-2-羧酸 | 152754-55-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-1-(3,3-二甲基-2-氧戊烷酰基)哌啶-2-羧酸
• 英文名称: (2S)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylic acid
• 英文别名: 2-Piperidinecarboxylic acid, 1-(3,3-dimethyl-1,2-dioxopentyl)-, (2S)-
• CAS: 152754-55-7
• 化学式: C₁₃H₂₁NO₄
• 分子量: 255.314
• InChiKey: GWXADOKFGBKLOD-VIFPVBQESA-N

物化性质

• 沸点：
  400.7±55.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  74.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  (S)-1-(3,3-二甲基-2-氧戊烷酰基)哌啶-2-羧酸 在 氯甲酸乙酯 、 三乙胺 、 肼 作用下， 以38%的产率得到(2S)-1-(3,3-dimethyl-2-oxopentanoyl)-N'-[(2S)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carbonyl]piperidine-2-carbohydrazide
  参考文献：
  名称：

  Neurotrophic pyrrolidines and piperidines, and related compositions and methods

  摘要：

  这项发明提供具有以下一般结构的化合物：这项发明还提供包含相同化合物的药物组合物，以及使用这些组合物治疗和预防由神经元损伤所特征化的疾病的方法。

  公开号：

  US06809107B1
• 作为产物：
  描述：

  magnesium,2-methylbutane,chloride 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 为溶剂， 反应 9.5h， 生成 (S)-1-(3,3-二甲基-2-氧戊烷酰基)哌啶-2-羧酸
  参考文献：
  名称：

  Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12

  摘要：

  The design and synthesis of high-affinity FKBP12 ligands is described. These compounds potently inhibit the cis-trans-peptidylprolyl isomerase (rotamase) activity catalyzed by FKBP12 with inhibition constants (K(i,app)) as low as 1 nM, yet they possess remarkable structural simplicity relative to FK506 and rapamycin, from which they are conceptually derived. The atomic structures of three FKBP12-ligand complexes and of one unbound ligand were determined by X-ray crystallography and are compared to the FKBP12-FK506 and FKBP12-rapamycin complexes.

  DOI：

  10.1021/ja00075a008

文献信息

• [EN] IMMUNOPHILIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE LIAISON À L'IMMUNOPHILINE ET LEURS UTILISATIONS
  申请人：UNIV CALIFORNIA

  公开号：WO2020163594A1

  公开（公告）日：2020-08-13

  Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.

  本文描述了免疫蛋白结合化合物以及治疗中枢神经系统疾病的方法，包括在主体的中枢神经系统外联合给予一种抗中枢神经系统疾病药物和本文描述的化合物。
• Targeted Covalent Inhibition of <i>Plasmodium</i> FK506 Binding Protein 35
  作者：Thomas C. Atack、Donald D. Raymond、Christa A. Blomquist、Charisse Flerida Pasaje、Patrick R. McCarren、Jamie Moroco、Henock B. Befekadu、Foxy P. Robinson、Debjani Pal、Lisl Y. Esherick、Alessandra Ianari、Jacquin C. Niles、William R. Sellers

  DOI：10.1021/acsmedchemlett.0c00272

  日期：2020.11.12

  protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35

  FK506结合蛋白35，FKBP35，已被认为是必需的疟疾酶。雷帕霉素和FK506在培养的寄生虫中表现出抗疟原虫活性。然而，由于FKBP的结合口袋的高度保守的性质和这些药物的免疫抑制特性，需要选择性地抑制FKBP35并且缺乏不良副作用的化合物。与人FKBP相比，FKBP35在雷帕霉素结合口袋附近包含一个半胱氨酸C106，为开发靶向疟原虫FKBP35的共价抑制剂提供了机会。在这里，我们合成了FKBP35的抑制剂，表明它们在模型细胞环境中直接结合FKBP35，选择性地共价修饰C106，并在血阶段培养的寄生虫中表现出抗疟原虫活性。
• Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay
  作者：Gene M Dubowchik、Jonathan L Ditta、John J Herbst、Sagarika Bollini、Alexander Vinitsky

  DOI：10.1016/s0960-894x(00)00045-7

  日期：2000.3

  Several fluoresceinated FKBP12 ligands have been prepared for a high-throughput fluorescence polarization assay. K(i)s for FKBP12 rotamase inhibition by these ligands range from 1.3 microM to 32 nM, and their design is based on X-ray crystal structures of FKBP12 complexed with known immunophilin ligands.

  已经准备好几种荧光素化的FKBP12配体用于高通量荧光偏振测定。这些配体抑制FKBP12旋转酶的K（i）为1.3 microM至32 nM，其设计基于与已知亲免蛋白配体复合的FKBP12的X射线晶体结构。
• Small Molecules for Imaging Protein-Protein Interactions
  申请人：Li C. King

  公开号：US20080085238A1

  公开（公告）日：2008-04-10

  A tissue is imaged to detect the presence of amyloid deposits or other target proteins prior to their aggregation into plaques, with the assistance of the administration of a labeled bifunctional compound of which one functionality binds to the target protein and the second functionality binds to a chaperone protein that is present in the tissue of interest. The two functionalities have different binding affinities, the target-binding functionality having the greater binding affinity, with the result that the bifunctional compound preferentially remains in the tissue when bound to the chaperone and then the target protein while bifunctional compound that is not bound to the target protein will leave the tissue. The inclusion of the chaperone allows the imaging process to detect the non-aggregated proteins by way of the label and the difference in kinetics of the binding to the chaperone and the target protein permits one to distinguish between binding of the bifunctional molecule to the chaperone only and binding to the chaperone and then to the target protein. Certain intermediates toward the synthesis of these bifunctional compounds are novel by themselves, and labeled bifunctional molecules in general that utilize a lysine linker are also disclosed as a novel class of compounds.

  一种组织被成像以检测淀粉样沉积物或其他靶蛋白质在聚集成斑块之前的存在，辅助使用一种带标记的双功能化合物的管理，其中一个功能性结合到靶蛋白质，第二个功能性结合到存在于感兴趣组织中的分子伴侣蛋白。这两种功能性具有不同的结合亲和力，结合到靶蛋白质的功能性具有更强的结合亲和力，结果是双功能化合物在与分子伴侣和靶蛋白质结合时更倾向于留在组织中，而未与靶蛋白质结合的双功能化合物会离开组织。包括分子伴侣可以使成像过程通过标记和结合到分子伴侣和靶蛋白质的结合动力学差异来检测非聚集的蛋白质，从而使人们能够区分双功能分子仅与分子伴侣结合和先与分子伴侣结合然后与靶蛋白质结合之间的区别。这些双功能化合物的合成中间体本身是新颖的，同时也公开了一种利用赖氨酸连接物的带标记双功能分子作为一种新颖类化合物。
• METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
  申请人：Revolution Medicines, Inc.

  公开号：US20210285955A1

  公开（公告）日：2021-09-16

  The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

  本公开提供了用于分析蛋白质-蛋白质界面的方法和试剂，例如展示蛋白质（例如FKBP家族成员、环肽酶家族成员或PIN1）与靶蛋白质之间的界面。在某些实施例中，靶蛋白质和/或展示蛋白质是细胞内蛋白质。在某些实施例中，靶蛋白质和/或展示蛋白质是哺乳动物蛋白质。